The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

With the New Year upon us millions of people will have made their New Year’s resolution to quit smoking. They will seek every avenue available to help them through the quitting process. They will try nicotine patches and gum, and many will opt for Pfizer’s Chantix to help them deal with the difficulties associated with quitting smoking. Smokers who decide to use Chantix to help them quit smoking should be aware that they could be getting more than they bargained for in some cases.

Over the past few months a sentiment has been growing alleging that Chantix may cause suicidal thoughts and psychotic behavior in some users. The FDA has launched an investigation into these allegations but no definitive results have been conveyed to the public as of thus far. The drug hits the market in Australia today and carries an additional warning for the possible risk of suicidal ideation associated with the drug. European authorities have decided to place a similar warning on their version of the drug, marketed as Champix.

The next few weeks could really have a huge impact on the future of Chantix in the U.S. and around the world. This is probably the most popular time of the year for people to quit smoking and if the over the next few weeks the FDA is bombarded with complaints of adverse reactions to Chantix the drug may soon carry additional warnings here in the U.S.

The FDA has asked physicians to closely monitor patients taking Chantix and has asked that all adverse reactions be reported to the Adverse Event Reporting System.

For more information on this subject, please refer to our section on Defective and Dangerous Products.

Comments are closed.

Of Interest